Capricor Therapeutics (CAPR) Tops Q3 EPS by 8c

Capricor Therapeutics (NASDAQ: CAPR) reported Q3 EPS of ($0.18), $0.08 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $0 versus the consensus estimate of $1.1 million.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Ennis (EBF) Reports In-Line Q1 EPS
• Carnival shares drop despite earnings beat on weak guidance